USA > Japan based Astellas Pharma Inc. acquires US based Mitobridge for $225 million (plus additional $225 million contingent on clinical development)

Astellas_Pharma_logo.svg Exercising its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their an R&D collaboration focused on discovering and developing novel drugs that target mitochondrial function, Astellas Pharma Inc. will now wholly own US based Mitobridge. The 2013 partnership agreements between Astellas and Mitobridge were formulated to discover and develop compounds that More …

BELGIUM > Japan’s Astellas to acquire Belgium based Ogeda for around $849.08 MM

Astellas_Pharma_logo.svg Japan based Astellas is slated to acquire Belgium based Ogeda for around €800 Mn ($849.08Mn). Under the agreement, Astellas will make an initial payment of €500Mn ($530.67 Mn) in consideration of 100% of the equity in Ogeda and an additional €300Mn ($318.41Mn) with attainment of certain clinical development and regulatory milestones for fezolinetant. The closing of the transaction is subject to certain conditions More …